| 前收盘价格 | 8.47 |
| 收盘价格 | 8.49 |
| 成交量 | 3,144,131 |
| 平均成交量 (3个月) | 4,029,720 |
| 市值 | 790,899,520 |
| 价格/销量 (P/S) | 3.61 |
| 股市价格/股市净资产 (P/B) | 6.58 |
| 52周波幅 | |
| 利润日期 | 21 Mar 2025 |
| 营业利益率 (TTM) | -43,073.68% |
| 稀释每股收益 (EPS TTM) | -0.990 |
| 季度收入增长率 (YOY) | 1,325.00% |
| 总债务/股东权益 (D/E MRQ) | 0.97% |
| 流动比率 (MRQ) | 5.70 |
| 营业现金流 (OCF TTM) | -74.98 M |
| 杠杆自由现金流 (LFCF TTM) | -44.05 M |
| 资产报酬率 (ROA TTM) | -33.64% |
| 股东权益报酬率 (ROE TTM) | -56.17% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Chimerix, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
-0.4
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.38 |
|
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.73% |
| 机构持股比例 | 56.44% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 11.00 (HC Wainwright & Co., 29.41%) | 保留 |
| 中 | 8.55 (0.59%) | |
| 低 | 8.50 (Jefferies, 0.00%) | 保留 |
| 平均值 | 9.35 (10.00%) | |
| 总计 | 3 保留 | |
| 平均价格@调整类型 | 8.45 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Jones Trading | 06 Mar 2025 | 8.55 (0.59%) | 保留 | 8.43 |
| HC Wainwright & Co. | 05 Mar 2025 | 11.00 (29.41%) | 保留 | 8.46 |
| 18 Feb 2025 | 11.00 (29.41%) | 购买 | 4.83 | |
| Jefferies | 05 Mar 2025 | 8.50 (0.00%) | 保留 | 8.46 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合